HIGHLIGHTS
- who: from the Division of Infectious Diseases have published the research: Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series, in the Journal: (JOURNAL) of 12/07/2018
- what: The authors retrospectively evaluated the safety and tolerability of DEF used as adjunctive treatment for IM. The study had several limitations; as a single-center retrospective case series examining a small number of patients due to rarity of the disease, recruiting a control group to conduct a case-control study was not feasible.
SUMMARY
Mucormycosis is a rare . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.